Downstream Bioprocessing Co-Op - Spring 2026

At Johnson & Johnson, we believe health is everything.

Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com

Job Function:
Career Programs

Job Sub Function:
Non-LDP Intern/Co-Op

Job Category:
Career Program

All Job Posting Locations:
Malvern, Pennsylvania, United States of America

Job Description:

Johnson & Johnson Innovative Medicine is recruiting for a Spring 2026 Co-Op in Downstream Bioprocessing, located in Malvern, PA.

Research & Development Co-Op Overview:

J&J R&D encompasses the development of sophisticated materials, process improvements, risk management and mechanical testing through the development process across all sectors including Pharmaceutical, Medical Device, Consumer and Corporate/Enterprise.

We offer a fast-paced cross-functional, technologically advanced, corporate environment, passionate about developing individual engineering and scientific skills.

You will have the opportunity to learn about anatomy, disease states, deformities and the surgical procedure/products used to address these conditions.

Life as an R&D Co-Op:

The R&D Co-Op program provides each student with real-life hands-on experience, coaching and mentoring, networking opportunities, as well as the opportunity to meet people from various schools throughout the country.

Each Co-Op will be assigned to a single function with a specific project for the 6-month term.

The typical Co-Op term is from Jan 2026– Jun 2026.

Key Responsibilities:

The TDS Proteins Development API organization is seeking a candidate interested in protein process development.

Various chromatography methods are utilized in the downstream sphere to purify protein molecules from process impurities and aggregates.

Assessing the impact of product- and process-related impurities such as high molecular weight species (HMWS) and host cell impurities, respectively, on final drug substance (DS) stability is crucial for development of potent biopharmaceutical products and for establishing downstream bioprocesses to effectively balance yield with product quality.

In this role, the Co-Op will...


* Study the impact of variable levels of HMW content and co-associated host impurities on stability-indicating attributes across two model antibody products.


* Purify biopharmaceutical products to achieve variable levels of HMW content through targeted control of cation exchange (CEX) and multi-modal anion exchange (MMAEX) process operating conditions.


* Evaluate stability-indicating quality attributes of drug substance across different HMWS experimental test ...